

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 025217-0122		SERIAL NO. Unassigned	
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				APPLICANT Barry L. REED et al.			
				FILING DATE 01/15/2004		GROUP ART UNIT Unassigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	5,082,866	01/92	WONG et al.	514	785	
	A2	5,256,647	10/93	MINASKANIAN et al.	514	24	
	A3	5,034,386	07/91	PECK et al.	514	212	
	A4	4,704,406	11/87	STANISIAUS et al.	514	570	
	A5	5,804,168	09/98	MURAD	424	439	
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	A6	43 34 553	04/95	FED. REP. OF GERMANY			
	A7	61-268631	11/86	JAPAN			
	A8	92/19271	11/92	WIPO			
	A9	30258/89	09/89	AUSTRALIA			
	A10	49984/1990	09/89	AUSTRALIA			
	A11	91413/91	06/92	AUSTRALIA			
	A12	96/30000	10/96	WIPO			
	A13	189 861	08/86	EUROPE			
	A14	0 552 405	07/93	EUROPE			
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	A15	R. J. FELDMANN et al., "Percutaneous Penetration of 14C Hydrocortisone In Man", <i>Arch Derm</i> , Vol. 94:649-651, (1966)					
	A16	M. F. COLDMAN et al., "Enhancement Of Percutaneous Absorption by The Use Of Volatile: Nonvolatile Systems And Vehicles", <i>Journal of Pharmaceutical Sciences</i> , Vol. 58(9):1098-1102, (1969)					
	A17	P. P. BHATT, et al., "Finite Dose Transport Of Drugs In Liquid Formulations Through Stratum Corneum: Analytical Solution To A Diffusion Model", <i>International Journal Of Pharmaceutics</i> , Elsevier science Publishers B. V., Vol. 50:197-203, (1989)					
	A18	NIMNI, U.S. Patent Number 4,820,742, "Internet: www.patents.ibm.com/fegi-bin/any2htm Document "Dual phase Solvent Carrier System", pp. 3, 4 and 6 out of 7 pages					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 15, 2004 (use as many sheets as necessary)				Complete if Known		
				Application Number		Unassigned
				Filing Date		01/15/2004
				First Named Inventor		Barry L. Reed
				Group Art Unit		Unassigned
				Examiner Name		Eiji MORI
Sheet	2	of	2	Attorney Docket Number		025217-0122

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	4,663,157		Brock	05/05/1987	
	A2	4,699,779		Palinczar	10/13/1987	
	A3	5,449,519		Wolf et al.	09/12/1995	
	A4	5,573,754		Kulkarni et al.	11/12/1996	
	A5	4,946,671		Bissett et al.	08/07/1990	
	A6	4,310,511		Holick	01/12/1982	
	A7	4,938,951		Leung et al.	07/03/1990	
	A8	5,679,374		Fanchon et al.	10/21/1997	
	A9	3,989,816		RAJADHYAKSHA	11/02/1976	
	A10	4,299,826		LUEDDERS	11/10/1981	
	A11	4,440,777		ZUPAN	04/03/1984	
	A12	4,557,934		COOPER	12/10/1985	
	A13	4,820,724		NIMNI	04/11/1989	
	A14	4,954,487		COOPER ET AL.	09/04/1990	
	A15	5,036,100		DEBOECK ET AL.	07/30/1991	
	A16	5,122,519		RITTER	06/16/1992	
	A17	5,487,898		LU ET AL.	01/30/1996	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	A9		EP 0608 322	B1	Deckner et al.	07/22/1998	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A10	BUCKS et al., Percutaneous Absorption of Hydroquinone in Humans: Effect of 1-Dodecylazacycloheptan-2-One (Azone) and the 2-Ethylhexyl Ester of 4-(Dimethylamino) Benzoic Acid (Escalol 507), Journal of Toxicology and Environmental Health, 24:279-289 (1988)	
	A11	Physicians' Desk Reference (49 Ed.) 1995, .pp. 1151-1152, Medical Economics Company, Inc., Montvale, N.J.	

Examiner Signature	Date Considered	
--------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Barry L. REED et al.
Title: DERMAL PENETRATION ENHANCERS AND
DRUG DELIVERY SYSTEMS INVOLVING
SAME
Div. Appln. Of: 09/910,780, filed 07/24/2001
Appln . No.: Unassigned
Filed: 01/15/2004
Examiner: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(d), before payment of the issue fee.

RELEVANCE OF EACH DOCUMENT

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-SB/08 be returned in accordance with MPEP §609.

STATEMENT

The undersigned hereby states in accordance with 37 C.F.R. §1.97(e)(1) that each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to filing of this Statement.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 20 January 2004 By S. A. Bent

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768